Table of Contents Author Guidelines Submit a Manuscript
Analytical Cellular Pathology
Volume 2018 (2018), Article ID 8651790, 8 pages
https://doi.org/10.1155/2018/8651790
Research Article

Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases

1Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2Research and Service Centre for Occupational Safety, Finnish Institute of Occupational Health, Helsinki, Finland
3Department of Pathology, HUSLAB and Helsinki University Hospital, Helsinki, Finland
4Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Correspondence should be addressed to Harriet Wikman; ed.eku@namkiw.h

Received 31 August 2017; Accepted 23 January 2018; Published 10 April 2018

Academic Editor: Giovanni Tuccari

Copyright © 2018 Wladimir Gerstenberger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. E. Scherer, R. Y. Lewis, D. Volonté et al., “Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo,” Journal of Biological Chemistry, vol. 272, no. 46, pp. 29337–29346, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Liu, M. Rudick, and R. G. W. Anderson, “Multiple functions of caveolin-1,” Journal of Biological Chemistry, vol. 277, no. 44, pp. 41295–41298, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. E. J. Smart, Y. S. Ying, P. A. Conrad, and R. G. Anderson, “Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation,” The Journal of Cell Biology, vol. 127, no. 5, pp. 1185–1197, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Wikman, J. K. Seppänen, V. K. Sarhadi et al., “Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays,” The Journal of Pathology, vol. 203, no. 1, pp. 584–593, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. G. R. Newman, L. Campbell, C. von Ruhland, B. Jasani, and M. Gumbleton, “Caveolin and its cellular and subcellular immunolocalisation in lung alveolar epithelium: implications for alveolar epithelial type I cell function,” Cell and Tissue Research, vol. 295, no. 1, pp. 111–120, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Mercier, J. F. Jasmin, S. Pavlides et al., “Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders,” Laboratory Investigation, vol. 89, no. 6, pp. 614–623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. V. A. Torres, J. C. Tapia, D. A. Rodríguez et al., “Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin,” Journal of Cell Science, vol. 119, no. 9, pp. 1812–1823, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Han, L. Zhang, Y. Zhou, and X. Yi, “Caveolin-1 regulates cell apoptosis and invasion ability in paclitaxel-induced multidrug-resistant A549 lung cancer cells,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 8, pp. 8937–8947, 2015. View at Google Scholar
  9. D. Chen and G. Che, “Value of caveolin‑1 in cancer progression and prognosis: emphasis on cancer‑associated fibroblasts, human cancer cells and mechanism of caveolin‑1 expression (review),” Oncology Letters, vol. 8, no. 4, pp. 1409–1421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Fu, F.-C. Chen, Q. Pan et al., “The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma,” OncoTargets and Therapy, vol. 10, pp. 819–835, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Deb, D. Sengupta, S. Kar et al., “Elucidation of caveolin 1 both as a tumor suppressor and metastasis promoter in light of epigenetic modulators,” Tumour Biology, vol. 35, no. 12, pp. 12031–12047, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. F. R. Balkwill, M. Capasso, and T. Hagemann, “The tumor microenvironment at a glance,” Journal of Cell Science, vol. 125, no. 23, pp. 5591–5596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Meng, S. Saxena, Y. Liu et al., “The phospho–caveolin-1 scaffolding domain dampens force fluctuations in focal adhesions and promotes cancer cell migration,” Molecular Biology of the Cell, vol. 28, no. 16, pp. 2190–2201, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. E. K. Sloan, D. R. Ciocca, N. Pouliot et al., “Stromal cell expression of caveolin-1 predicts outcome in breast cancer,” The American Journal of Pathology, vol. 174, no. 6, pp. 2035–2043, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. A. K. Witkiewicz, A. Dasgupta, F. Sotgia et al., “An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers,” The American Journal of Pathology, vol. 174, no. 6, pp. 2023–2034, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Ren, F. Liu, Y. Zhu et al., “Absence of caveolin-1 expression in carcinoma-associated fibroblasts of invasive micropapillary carcinoma of the breast predicts poor patient outcome,” Virchows Archiv, vol. 465, no. 3, pp. 291–298, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Martins, F. Beça, B. Sousa, F. Baltazar, J. Paredes, and F. Schmitt, “Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: key events in the progression from an in situ to an invasive breast carcinoma,” Cell Cycle, vol. 12, no. 16, pp. 2684–2690, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Ma, L. Liu, W. Nie et al., “Prognostic role of caveolin in breast cancer: a meta-analysis,” The Breast, vol. 22, no. 4, pp. 462–469, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Zhao, Y. He, J. Gao et al., “Caveolin-1 expression level in cancer associated fibroblasts predicts outcome in gastric cancer,” PLoS One, vol. 8, no. 3, article e59102, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. K. N. Wu, M. Queenan, J. R. Brody et al., “Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival,” Cell Cycle, vol. 10, no. 24, pp. 4250–4255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Ayala, M. Morello, A. Frolov et al., “Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression,” The Journal of Pathology, vol. 231, no. 1, pp. 77–87, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Shan, H. Lu, H. Ji et al., “Loss of stromal caveolin-1 expression: a novel tumor microenvironment biomarker that can predict poor clinical outcomes for pancreatic cancer,” PLoS One, vol. 9, no. 6, article e97239, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Zhao, F. H. Han, S. B. Yang, L. X. Hua, J. H. Wu, and W. H. Zhan, “Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival,” World Journal of Gastroenterology, vol. 21, no. 4, pp. 1140–1147, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Jia, N. Wang, J. Wang et al., “Down-regulation of stromal caveolin-1 expression in esophageal squamous cell carcinoma: a potent predictor of lymph node metastases, early tumor recurrence, and poor prognosis,” Annals of Surgical Oncology, vol. 21, no. 1, pp. 329–336, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. D. H. Jensen, M. H. Therkildsen, and E. Dabelsteen, “A reverse Warburg metabolism in oral squamous cell carcinoma is not dependent upon myofibroblasts,” Journal of Oral Pathology & Medicine, vol. 44, no. 9, pp. 714–721, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. X. J. Shen, H. Zhang, G. S. Tang et al., “Caveolin-1 is a modulator of fibroblast activation and a potential biomarker for gastric cancer,” International Journal of Biological Sciences, vol. 11, no. 4, pp. 370–379, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. He, X. Zhao, J. Gao et al., “Quantum dots-based immunofluorescent imaging of stromal fibroblasts caveolin-1 and light chain 3B expression and identification of their clinical significance in human gastric cancer,” International Journal of Molecular Sciences, vol. 13, no. 12, pp. 13764–13780, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Di Vizio, M. Morello, F. Sotgia, R. G. Pestell, M. R. Freeman, and M. P. Lisanti, “An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease spread and epithelial Akt activation,” Cell Cycle, vol. 8, no. 15, pp. 2420–2424, 2009. View at Publisher · View at Google Scholar
  30. L. Righi, M. C. Cavallo, G. Gatti et al., “Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis,” American Journal of Clinical Pathology, vol. 141, no. 6, pp. 816–827, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Vered, M. Lehtonen, L. Hotakainen et al., “Caveolin-1 accumulation in the tongue cancer tumor microenvironment is significantly associated with poor prognosis: an in-vivo and in-vitro study,” BMC Cancer, vol. 15, no. 1, p. 25, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. J. S. Koo, S. Park, S. I. Kim, S. Lee, and B. W. Park, “The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer,” Tumour Biology, vol. 32, no. 4, pp. 787–799, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Kim, H. Kim, and J. S. Koo, “Expression of caveolin-1, caveolin-2 and caveolin-3 in thyroid cancer and stroma,” Pathobiology, vol. 79, no. 1, pp. 1–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Deutsch, M. Wrage, S. Koops et al., “Opposite roles of FOXA1 and NKX2-1 in lung cancer progression,” Genes, Chromosomes & Cancer, vol. 51, no. 6, pp. 618–629, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Zhan, X.-K. Shen, Q. Qian et al., “Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas,” Oncology Reports, vol. 27, no. 4, pp. 1072–1078, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Li, H. Chen, L. Diao, Y. Zhang, C. Xia, and F. Yang, “Caveolin-1 and VEGF-C promote lymph node metastasis in the absence of intratumoral lymphangiogenesis in non-small cell lung cancer,” Tumori Journal, vol. 96, no. 5, pp. 734–743, 2010. View at Publisher · View at Google Scholar
  37. H. L. Chen, L. F. Fan, J. Gao, J. P. Ouyang, and Y. X. Zhang, “Differential expression and function of the caveolin-1 gene in non-small cell lung carcinoma,” Oncology Reports, vol. 25, no. 2, pp. 359–366, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Cassoni, L. Daniele, E. Maldi et al., “Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases,” Histopathology, vol. 55, no. 1, pp. 20–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. C. C. Ho, S. H. Kuo, P. H. Huang, H. Y. Huang, C. H. Yang, and P. C. Yang, “Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy,” Lung Cancer, vol. 59, no. 1, pp. 105–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S. H. Yoo, Y. S. Park, H. R. Kim et al., “Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung,” Lung Cancer, vol. 42, no. 2, pp. 195–202, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Chen, C. Shen, H. Du, Y. Zhou, and G. Che, “Duplex value of caveolin-1 in non-small cell lung cancer: a meta analysis,” Familial Cancer, vol. 13, no. 3, pp. 449–457, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. E. M. Bertino, T. M. Williams, S. P. Nana-Sinkam et al., “Stromal caveolin-1 is associated with response and survival in a phase II trial of nab-paclitaxel with carboplatin for advanced NSCLC patients,” Clinical Lung Cancer, vol. 16, no. 6, pp. 466–474.e4, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Y. Luan, T. N. Zhu, Y. J. Cui et al., “Expression of caveolin-1 is correlated with lung adenocarcinoma proliferation, migration, and invasion,” Medical Oncology, vol. 32, no. 7, p. 207, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Duregon, R. Senetta, L. Bertero et al., “Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas,” Tumor Biology, vol. 39, no. 2, article 101042831769431, 2017. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Onion, M. Isherwood, N. Shridhar et al., “Multicomponent analysis of the tumour microenvironment reveals low CD8 T cell number, low stromal caveolin-1 and high tenascin-C and their combination as significant prognostic markers in non-small cell lung cancer,” Oncotarget, vol. 9, no. 2, pp. 1760–1771, 2018. View at Publisher · View at Google Scholar
  46. K. Shimizu, K. Kirita, K. Aokage et al., “Clinicopathological significance of caveolin-1 expression by cancer-associated fibroblasts in lung adenocarcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 143, no. 2, pp. 321–328, 2017. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Sotgia, F. Del Galdo, M. C. Casimiro et al., “Caveolin-1−/− null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts,” The American Journal of Pathology, vol. 174, no. 3, pp. 746–761, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. U. E. Martinez-Outschoorn, S. Pavlides, D. Whitaker-Menezes et al., “Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors,” Cell Cycle, vol. 9, no. 12, pp. 2423–2433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Bonuccelli, D. Whitaker-Menezes, R. Castello-Cros et al., “The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts,” Cell Cycle, vol. 9, no. 10, pp. 1960–1971, 2010. View at Publisher · View at Google Scholar · View at Scopus